Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Investment Securities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Gains from Investment Securities for 14 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 4749.64% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, up 980.0%, and an annual FY2025 reading of $5.8 million, up 11.09% over the prior year.
  • Gains from Investment Securities was $6.6 million for Q4 2025 at Enanta Pharmaceuticals, up from $5.8 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $22.7 million in Q3 2022 and bottomed at -$799000.0 in Q1 2024.
  • Average Gains from Investment Securities over 5 years is $3.6 million, with a median of $3.7 million recorded in 2023.
  • The sharpest move saw Gains from Investment Securities plummeted 572.78% in 2024, then soared 52454.55% in 2025.
  • Year by year, Gains from Investment Securities stood at $607000.0 in 2021, then grew by 1.81% to $618000.0 in 2022, then tumbled by 70.39% to $183000.0 in 2023, then dropped by 25.14% to $137000.0 in 2024, then soared by 4749.64% to $6.6 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ENTA at $6.6 million in Q4 2025, $5.8 million in Q3 2025, and $6.0 million in Q2 2025.